Compliance Insight podcast Series

The two companies will be exhibiting together after Gerresheimer’s December 2024 acquisition of Bormioli.

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

This investment is additional to and separate from £11 million that was announced in the fall of 2024 for creating new jobs and expanding Almac’s global analytical services capabilities.

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

The collaboration will leverage Thermo Fisher’s Accelerator Drug Development stable of solutions, which was launched in the fall of 2024.

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.